Chromogranin A levels and mortality in patients with severe sepsis

Chih Hsin Hsu; Luis F. Reyes; Carlos J. Orihuela; Ricardo Buitrago; Antonio Anzueto; Nilam J. Soni; Stephanie Levine; Jay Peters; Cecilia A. Hinojosa; Stefano Aliberti; Oriol Sibila; Alejandro Rodriguez; James D. Chalmers; Ignacio Martin-Loeches; Jose Bordon; Jose Blanquer; Francisco Sanz; Pedro J. Marcos; Jordi Rello; Jordi Solé-Violán; Marcos I. Restrepo

doi:10.3109/1354750X.2015.1046932

Chromogranin A levels and mortality in patients with severe sepsis

Chih Hsin Hsu, Luis F. Reyes, Carlos J. Orihuela, Ricardo Buitrago, Antonio Anzueto, Nilam J. Soni, Stephanie Levine, Jay Peters, Cecilia A. Hinojosa, Stefano Aliberti, Oriol Sibila, Alejandro Rodriguez, James D. Chalmers, Ignacio Martin-Loeches, Jose Bordon, Jose Blanquer, Francisco Sanz, Pedro J. Marcos, Jordi Rello, Jordi Solé-ViolánMarcos I. Restrepo

Resultado de la investigación: Article › revisión exhaustiva

7 Citas (Scopus)

Resumen

Context: Chromogranin A (CgA) is a novel biomarker with potential to assess mortality risk of patients with severe sepsis.Objective: Assess association of CgA levels and mortality risk of severely septic patients.Methods: Serum CgA levels were measured in 50 hospitalized, severely septic patients with organ failure <48 h.Results: Higher CgA levels trended toward higher ICU and hospital mortality. Patients without cardiovascular disease who died in the ICU had higher median (IQR) CgA levels 602.3 (343.3, 1134.3) ng/ml versus 205.5 (130.7, 325.9) ng/ml, p = 0.01.Conclusions: High CgA levels predict ICU mortality in severely septic patients without prior cardiovascular disease.

Idioma original	English (US)
Páginas (desde-hasta)	171-176
Número de páginas	6
Publicación	Biomarkers
Volumen	20
N.º	3
DOI	https://doi.org/10.3109/1354750X.2015.1046932
Estado	Published - abr 3 2015

ASJC Scopus subject areas

Biochemistry
Clinical Biochemistry
Health, Toxicology and Mutagenesis

Acceder al documento

10.3109/1354750X.2015.1046932

Otros archivos y enlaces

Citar esto

Hsu, C. H., Reyes, L. F., Orihuela, C. J., Buitrago, R., Anzueto, A., Soni, N. J., Levine, S., Peters, J., Hinojosa, C. A., Aliberti, S., Sibila, O., Rodriguez, A., Chalmers, J. D., Martin-Loeches, I., Bordon, J., Blanquer, J., Sanz, F., Marcos, P. J., Rello, J., ... Restrepo, M. I. (2015). Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 20(3), 171-176. https://doi.org/10.3109/1354750X.2015.1046932

Hsu, CH, Reyes, LF, Orihuela, CJ, Buitrago, R, Anzueto, A, Soni, NJ, Levine, S , Peters, J, Hinojosa, CA, Aliberti, S, Sibila, O, Rodriguez, A, Chalmers, JD, Martin-Loeches, I, Bordon, J, Blanquer, J, Sanz, F, Marcos, PJ, Rello, J, Solé-Violán, J & Restrepo, MI 2015, 'Chromogranin A levels and mortality in patients with severe sepsis', Biomarkers, vol. 20, n.º 3, pp. 171-176. https://doi.org/10.3109/1354750X.2015.1046932

@article{d61026c737db47bda3f707443cbee70f,

title = "Chromogranin A levels and mortality in patients with severe sepsis",

abstract = "Context: Chromogranin A (CgA) is a novel biomarker with potential to assess mortality risk of patients with severe sepsis.Objective: Assess association of CgA levels and mortality risk of severely septic patients.Methods: Serum CgA levels were measured in 50 hospitalized, severely septic patients with organ failure <48 h.Results: Higher CgA levels trended toward higher ICU and hospital mortality. Patients without cardiovascular disease who died in the ICU had higher median (IQR) CgA levels 602.3 (343.3, 1134.3) ng/ml versus 205.5 (130.7, 325.9) ng/ml, p = 0.01.Conclusions: High CgA levels predict ICU mortality in severely septic patients without prior cardiovascular disease.",

keywords = "Biological marker, Chromogranin A, cardiovascular diseases, mortality, sepsis",

author = "Hsu, {Chih Hsin} and Reyes, {Luis F.} and Orihuela, {Carlos J.} and Ricardo Buitrago and Antonio Anzueto and Soni, {Nilam J.} and Stephanie Levine and Jay Peters and Hinojosa, {Cecilia A.} and Stefano Aliberti and Oriol Sibila and Alejandro Rodriguez and Chalmers, {James D.} and Ignacio Martin-Loeches and Jose Bordon and Jose Blanquer and Francisco Sanz and Marcos, {Pedro J.} and Jordi Rello and Jordi Sol{\'e}-Viol{\'a}n and Restrepo, {Marcos I.}",

note = "Funding Information: All authors have no conflict of interest. Dr. Restrepo{\textquoteright}s time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health. Publisher Copyright: {\textcopyright} 2015 Informa UK Ltd. All rights reserved.",

year = "2015",

month = apr,

day = "3",

doi = "10.3109/1354750X.2015.1046932",

language = "English (US)",

volume = "20",

pages = "171--176",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Chromogranin A levels and mortality in patients with severe sepsis

AU - Hsu, Chih Hsin

AU - Reyes, Luis F.

AU - Orihuela, Carlos J.

AU - Buitrago, Ricardo

AU - Anzueto, Antonio

AU - Soni, Nilam J.

AU - Levine, Stephanie

AU - Peters, Jay

AU - Hinojosa, Cecilia A.

AU - Aliberti, Stefano

AU - Sibila, Oriol

AU - Rodriguez, Alejandro

AU - Chalmers, James D.

AU - Martin-Loeches, Ignacio

AU - Bordon, Jose

AU - Blanquer, Jose

AU - Sanz, Francisco

AU - Marcos, Pedro J.

AU - Rello, Jordi

AU - Solé-Violán, Jordi

AU - Restrepo, Marcos I.

N1 - Funding Information: All authors have no conflict of interest. Dr. Restrepo’s time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health. Publisher Copyright: © 2015 Informa UK Ltd. All rights reserved.

PY - 2015/4/3

Y1 - 2015/4/3

N2 - Context: Chromogranin A (CgA) is a novel biomarker with potential to assess mortality risk of patients with severe sepsis.Objective: Assess association of CgA levels and mortality risk of severely septic patients.Methods: Serum CgA levels were measured in 50 hospitalized, severely septic patients with organ failure <48 h.Results: Higher CgA levels trended toward higher ICU and hospital mortality. Patients without cardiovascular disease who died in the ICU had higher median (IQR) CgA levels 602.3 (343.3, 1134.3) ng/ml versus 205.5 (130.7, 325.9) ng/ml, p = 0.01.Conclusions: High CgA levels predict ICU mortality in severely septic patients without prior cardiovascular disease.

AB - Context: Chromogranin A (CgA) is a novel biomarker with potential to assess mortality risk of patients with severe sepsis.Objective: Assess association of CgA levels and mortality risk of severely septic patients.Methods: Serum CgA levels were measured in 50 hospitalized, severely septic patients with organ failure <48 h.Results: Higher CgA levels trended toward higher ICU and hospital mortality. Patients without cardiovascular disease who died in the ICU had higher median (IQR) CgA levels 602.3 (343.3, 1134.3) ng/ml versus 205.5 (130.7, 325.9) ng/ml, p = 0.01.Conclusions: High CgA levels predict ICU mortality in severely septic patients without prior cardiovascular disease.

KW - Biological marker

KW - Chromogranin A

KW - cardiovascular diseases

KW - mortality

KW - sepsis

UR - http://www.scopus.com/inward/record.url?scp=84940027182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940027182&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2015.1046932

DO - 10.3109/1354750X.2015.1046932

M3 - Article

C2 - 26154393

AN - SCOPUS:84940027182

SN - 1354-750X

VL - 20

SP - 171

EP - 176

JO - Biomarkers

JF - Biomarkers

IS - 3

ER -

Chromogranin A levels and mortality in patients with severe sepsis

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto